Novo Nordisk’s Awiqli first FDA-approved once-weekly basal insulin
The type 2 diabetes injection reduces administration frequency from daily to once per week, enhancing convenience for patients.
The US Food and Drug Administration (FDA) has approved a once-weekly, long-acting basal insulin treatment for type 2 diabetes for the first time.
Novo Nordisk’s Awiqli (insulin icodec-abae) injection 700 units/mL provides a more convenient alternative to daily insulin as it is delivered via a prefilled pen.
The subcutaneous treatment is authorised as
Already a member? Sign-in
